Progentos is developing a new approach to treating multiple sclerosis that stimulates the body’s natural repair mechanisms.

CAVALRY Biosciences is developing novel therapeutics by engineering tissue-selective growth factors and cytokines to harness their potent biology and build better treatments for both rare and chronic diseases.

Eikonizo is developing brain penetrant and peripherally-restricted small molecule HDAC6 inhibitors to improve the treatment of human disease.

Zag Bio is working to discover and develop therapies targeted directly to the thymus, with the goal of generating central immune tolerance.

Ribonaut Therapeutics is a stealth company developing therapeutics for undruggable targets.

TippingPoint Biosciences is developing a new class of therapeutics that can specifically modulate chromatin networks in disease. 

Integrated Biosciences combines synthetic biology and machine learning to control cellular stress responses for next-generation therapeutics.

Volnay is building transformative and commercially viable cell and gene ventures centered on product development and technology innovation.

ImmunOs Therapeutics is developing the next generation of immunomodulatory therapies that have a role in the innate immune system for cancer and autoimmune diseases.

Developing antibody based targeted therapies against membrane and extracellular proteins that drive underlying disease biology.

Nuvig Therapeutics is advancing transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis and rebalance immune function in autoimmune and chronic inflammation diseases.

Jupiter Bioventures LLC is a company creation engine – focused on de-risking early-stage projects.

ARase Therapeutics is developing first-in-class inhibitors that target cancer signaling pathways.

Tune Therapeutics is developing next-generation cell-therapies using their platform of targeted epigenetic modifiers.

Founded by Mission BioCapital, Arclight is building a portfolio of neurodegeneration companies to accelerate transformative neuroscience.

Founded by Mission BioCapital, Arclight is building a portfolio of neurodegeneration companies to accelerate transformative neuroscience.

Ambagon is drugging the undruggable by manipulating interactions with the adaptor protein 14-3-3.

Developing a new class of medicines based on breakthrough discoveries in enzyme biology.

Unlocking the power of plants to create the next generation of animal-based food substitutes.

Telo is developing novel precision medicine to reverse cancer cell immortality. 

Dren reprograms natural killer cells to attack cancer cells by leveraging antibody-dependent cellular cytotoxicity. 

Developing therapies for patients with rare diseases of  protein and lipid glycosylation. 

Arkuda Therapeutics is advancing novel targeted medicines for the treatment of frontotemporal dementia. 

Alessa Therapeutics is focused on development, clinical validation and commercialization of local, sustained drug delivery for solid tumors. 

Mediar Therapeutics is drugging the myofibroblast as a new approach to halt and reverse fibrosis. 

Shape Therapeutics is harnessing the potential of RNA therapeutics to shape the future of gene therapy.  

Mammoth Biosciences is harnessing the diversity of nature to power the next generation of CRISPR products.

Nocion Therapeutics is revolutionizing the treatment of neurogenic inflammation by silencing inflamed nociceptors. 

QurAlis is developing breakthrough precision medicines for ALS and other neurologic diseases.

Kit offers comprehensive at-home health & lab testing solutions.

Graphwear Technologies is pioneering wearable, non-invasive sensors for continuous monitoring of glucose levels without needles. 

Starting with sushi-grade salmon, Wildtype is pioneering cellular agriculture to grow delicious cuts of our favorite seafood.

Leveraging proprietary microbiome research to develop products that naturally promote the clarity, vibrance, and resilience of skin.

Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.

Photoswitch is creating advanced tools to drive next-generation membrane biology discoveries.

LogicInk is a lifestyle sensor company, developing bio-chemical Signals that can be worn or applied daily.

PanTher is developing treatments for solid tumors through minimally invasive implantable modalities for localized cancer therapy. 

Vaxess Technologies is transforming delivery of vaccines and therapeutics through the MIMIX patch, making vaccines more effective and accessible. 

Avexegen is developing novel therapies to promote and restore gut health.

Epiodyne is developing breakthrough medicines to provide patients with safe options to break their opioid dependence, fight the spread of opioid use disorders, and provide non-addictive pain relief.

Revolutionizing intraoperative histology with their NIO Laser Imaging System and AI-powered image analysis.

Applaud Medical aims to improve treatment methods, patient experiences and medical costs for all patients experiencing the effects of kidney stones.

Vivace Therapeutics is an oncology-focused small molecule drug discovery and development company.

Symic Biomedical is developing therapeutics for fibrotic diseases by targeting the extracellular matrix.

SiteOne is developing a completely new class of non-opioid treatments for pain which selectively interrupt electrical signals from hyperexcitable, peripheral sensory nerves before they engage the central nervous system.

Circle Pharma operates an indication-agnostic discovery engine for the development of cell permeable macrocyclic peptide therapeutics.

Magnap is developing a minimally-invasive surgical device to prevent airway collapse during sleep.

Tangible Science is committed to creating products to make a more comfortable contact lens.

Myka Labs is pioneering a magnetic and minimally invasive surgical device to allow complex GI tract interventions.

Bolt Threads is a material solutions company inspired by nature to develop materials for a more sustainable future. 

Fluxion Biosciences develops microfluidic tools for cellular analysis and liquid biopsy tests.